Literature DB >> 29296965

Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.

Shoko Nakayama1, Taiji Yokote1, Toshikazu Akioka1, Nobuya Hiraoka1, Uta Nishiwaki1, Takuji Miyoshi1, Kazuki Iwaki1, Ayami Takayama1, Yuki Masuda1, Jun Hatooka1, Mayumi Fujimoto1, Yasuichiro Nishimura2, Motomu Tsuji3.   

Abstract

Regulatory T cells (Tregs) specifically express the transcription factor forkhead box P3 (FOXP3) and contribute to tumor progression. FOXP3-positive cells have been recently proven to be heterogeneous in phenotype and function, including effector Tregs (eTregs), naïve Tregs, and non-Tregs, which harbor no suppressive function. Therefore, it is crucial to investigate the "true Treg (eTreg)" population, rather than the entire FOXP3 population, with regards to their effect on tumor immunity. In particular, in diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), FOXP3-positive cells correlated with a better prognosis. The present study sought to evaluate the relationship between the prognosis of DLBCL, NOS patients and the infiltration of true Tregs by employing dual immunostaining with FOXP3 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative immunomodulatory known to be expressed by eTregs, but not by non-Tregs. Lymph nodes from 82 nodal DLBCL, NOS patients were stained with anti-FOXP3 and anti-CTLA-4 antibodies. A high infiltration of FOXP3-positive cells was associated with a significantly better prognosis than patients with low levels of FOXP3-positive cells for overall survival (OS) (P = .0233). In sharp contrast, a high infiltration of FOXP3/CTLA-4 double-positive cells was significantly associated with a poor prognosis than patients with low levels of FOXP3/CTLA-4 double-positive cells for OS (P = .0121) and progression-free survival (P = .0171), independent of the international prognostic index. FOXP3/CTLA-4 double-positive cells, eTregs, play an important role in DLBCL, NOS progression.

Entities:  

Year:  2017        PMID: 29296965      PMCID: PMC5728452          DOI: 10.1182/bloodadvances.2016000885

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  35 in total

Review 1.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

2.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Authors:  T P Miller; T M Grogan; S Dahlberg; C M Spier; R M Braziel; P M Banks; K Foucar; C R Kjeldsberg; N Levy; B N Nathwani
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

3.  Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP.

Authors:  Rita Coutinho; Andrew J Clear; Emanuele Mazzola; Andrew Owen; Paul Greaves; Andrew Wilson; Janet Matthews; Abigail Lee; Rute Alvarez; Maria Gomes da Silva; José Cabeçadas; Donna Neuberg; Maria Calaminici; John G Gribben
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

Review 4.  FOXP3 ensembles in T-cell regulation.

Authors:  Bin Li; Arabinda Samanta; Xiaomin Song; Keiji Furuuchi; Kathryn T Iacono; Sarah Kennedy; Makoto Katsumata; Sandra J Saouaf; Mark I Greene
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

Review 5.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 6.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

7.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.

Authors:  Shoko Nakayama; Taiji Yokote; Yuji Hirata; Toshikazu Akioka; Takuji Miyoshi; Nobuya Hiraoka; Kazuki Iwaki; Ayami Takayama; Uta Nishiwaki; Yuki Masuda; Yasuichiro Nishimura; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Am J Surg Pathol       Date:  2014-02       Impact factor: 6.394

Review 10.  Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease?

Authors:  M A Shipp
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

View more
  9 in total

1.  High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.

Authors:  Hideaki Saito; Hiroaki Miyoshi; Hirohiko Shibayama; Jun Toda; Shinsuke Kusakabe; Michiko Ichii; Jiro Fujita; Kentaro Fukushima; Tetsuo Maeda; Masao Mizuki; Kenji Oritani; Masao Seto; Takafumi Yokota; Yuzuru Kanakura; Naoki Hosen; Koichi Ohshima
Journal:  Int J Hematol       Date:  2021-03-25       Impact factor: 2.490

2.  Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.

Authors:  Yang Zhao; Hui Xu; Mingzhi Zhang; Ling Li
Journal:  Front Genet       Date:  2022-05-04       Impact factor: 4.772

3.  Prognostic significance of CD4-positive regulatory T cells in tumor draining lymph nodes from patients with bladder cancer.

Authors:  Ali Ariafar; Yasmin Vahidi; Maryam Fakhimi; Ardalan Asadollahpour; Nasrollah Erfani; Zahra Faghih
Journal:  Heliyon       Date:  2020-12-01

4.  Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer.

Authors:  Hirokazu Matsushita; Kosei Hasegawa; Sho Sato; Daisuke Shintani; Yukari Kobayashi; Nao Fujieda; Akira Yabuno; Tadaaki Nishikawa; Keiichi Fujiwara; Kazuhiro Kakimi
Journal:  BMC Cancer       Date:  2022-04-21       Impact factor: 4.638

5.  Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples.

Authors:  Kevin B Givechian; Kamil Wnuk; Chad Garner; Stephen Benz; Hermes Garban; Shahrooz Rabizadeh; Kayvan Niazi; Patrick Soon-Shiong
Journal:  NPJ Genom Med       Date:  2018-06-13       Impact factor: 8.617

6.  Prominent immune signatures of T cells are specifically associated with indolent B-cell lymphoproliferative disorders and predict prognosis.

Authors:  Shuhua Yi; Yu Zhang; Wenjie Xiong; Weiwei Chen; Zhaohua Hou; Yang Yang; Yuting Yan; Yunbo Wei; Rui Cui; Huijun Wang; Zhen Yu; Heng Li; Zengjun Li; Wei Liu; Rui Lv; Tingyu Wang; Kun Ru; Dehui Zou; Minglei Shu; Lugui Qiu; Di Yu
Journal:  Clin Transl Immunology       Date:  2020-01-22

7.  The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer.

Authors:  Noriko Goda; Shinsuke Sasada; Hideo Shigematsu; Norio Masumoto; Koji Arihiro; Hiroyoshi Nishikawa; Shimon Sakaguchi; Morihito Okada; Takayuki Kadoya
Journal:  Discov Oncol       Date:  2022-04-19

Review 8.  Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.

Authors:  Kamira Maharaj; Angimar Uriepero; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

9.  Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma.

Authors:  Michihito Tagawa; Chihiro Kurashima; Satoshi Takagi; Naoya Maekawa; Satoru Konnai; Genya Shimbo; Kotaro Matsumoto; Hisashi Inokuma; Keiko Kawamoto; Kazuro Miyahara
Journal:  PLoS One       Date:  2018-07-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.